Atopic Dermatitis Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018
Atopic Dermatitis Pipeline Drugs Assessment
Atopic dermatitis is a chronic, pruritic inflammatory skin disease with unknown origin. It generally occurs in children but affects a substantial number of adults.Symptoms include dry skin, itching, red to brownish-grey patches especially on hands, neck, upper feet, legs, inside the bend of elbows, knees and other parts of the body.
Atopic dermatitis generally examined through the physical examination. No cure has been found for atopic dermatitis, but the treatment is given for relieving the symptoms. Treatment may include topical applications to relieve the itching, oral drugs to control the inflammation and drugs for infection control.Food and Drug Administration (FDA) has recently approved a new, injectable monoclonal antibody, dupilumab for the treatment of severe atopic dermatitis.
By route of administration, atopic dermatitis pipeline drugs are segmented into
By Trial Phase, Atopic Dermatitis pipeline drugs are segmented as:
- Preclinical Trials
- Phase 1
- Phase 2
- Phase 3
By company, Atopic Dermatitis pipeline drugs are segmented into
- AbbVie Inc. (U.S.)
- Sterna Biologicals GmbH & Co. KG (Germany)
- Santalis Pharmaceuticals, Inc. (U.S.)
- MedImmune LLC (U.S.)
- Eli Lilly and Company (U.S.)
- Regeneron Pharmaceutical (U.S.)
- Sienna Biopharmaceuticals (U.S.)
Currently, there is no availability of effective treatments to treat atopic dermatitis. Most of the drugs are used to relieve the symptoms. Two Janus kinase inhibitors approved for rheumatoid arthritis and myelodysplasia. One of these drugs isstudied for atopic dermatitis but drug is not actively developed now. Many Janus kinase inhibitors are in clinical trial stages for treatment of atopic dermatitis.
- In March 2017, LEO Pharma announced positive results from a Phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD).
- In January 2017, AbbVie announced that the U.S. FDA granted Breakthrough Therapy Designation for the investigational, once-daily oral JAK1-selective inhibitor upadacitinib (ABT-494) in adult patients with moderate to severe atopic dermatitis who are candidates for systemic therapy.
Atopic Dermatitis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Atopic Dermatitis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Atopic Dermatitis disease pipeline drugs development. This report studies the dynamics of the Atopic Dermatitis Disease Pipeline Drugs i.e. drivers, challenges, and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Atopic Dermatitis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Key Features of the Report:
- Provides the information related to universities and research institutes working in the therapeutics development
- Report comprehensively covers the all active and discontinued studies
- Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
- Presents the prominent targets for drug development in each stage of clinical trial
- Provides the in-depth analysis of each drug candidates in the clinical trial phases